QT Imaging Holdings, Inc. (QTI) generates news tied to medical device commercialization, breast imaging technology and public company reporting. The company describes itself as focused on breast health management through radiation-free imaging technology, with the Breast Acoustic CT Scanner as its main named system.
QTI news often centers on the progress of its Breast Acoustic CT platform. Relevant company updates include scanner commercialization, distribution and direct commercial activity, development work on reconstruction and quantitative imaging algorithms, clinical workflow, the QTI Precision Pathway cloud platform and collaboration related to a multimodality viewer and quantitative analysis.
Regulatory and quality-related announcements are also important for this issuer because the company operates in a medical device category. QT Imaging has announced FDA clearance for its scanner as an adjunctive breast imaging device for adult women, Israeli Ministry of Health registration for commercialization in Israel and completion of an FDA routine inspection with zero Form 483 observations.
Financial and governance news adds another layer for QTI. The company's releases and filings include quarterly financial results, financing activity, shareholder letters, annual meeting results, executive appointments and equity incentive plan matters. Regular review of QTI news helps connect the company's breast imaging technology claims with commercialization updates, regulatory disclosures and public company governance events.
QT Imaging (QTI) announced that distribution partner NXC Imaging entered a national purchasing agreement with Premier covering its Breast Acoustic CT scanner. The agreement provides access to nearly 4,400 hospitals and health systems nationwide. Eligible Premier members can obtain pre-negotiated pricing and terms through NXC Imaging, establishing a purchasing pathway for providers evaluating the supplemental breast imaging technology.
QT Imaging (Nasdaq: QTI) announced that CPT Category III code 1079T for 3D breast acoustic imaging is effective October 1, 2026.
The date is three months earlier than the company anticipated. Providers can now use a dedicated procedure-reporting code for the service. QT Imaging said this enables immediate implementation work with imaging centers, physicians, and payers while it builds reimbursement infrastructure.
QT Imaging (QTI) CEO Raluca Dinu will ring Nasdaq’s closing bell on October 2, 2026, for Breast Cancer Awareness Month. The ceremony will take place at Nasdaq MarketSite in New York City at 4:00 p.m. ET. QT Imaging executives, team members and partners will join her.
QT Imaging (QTI) will be honored at Premier’s 2026 Supplier Innovation Celebration for its FDA-cleared Breast Acoustic CT™ Scanner. The recognition will take place during Premier’s Breakthroughs Conference and Exhibition in October 2026.
The annual Innovation Celebration highlights healthcare technologies launched throughout the year that help improve community health. Honorees are chosen by a national committee of clinicians, physicians, and supply chain experts who evaluate each technology’s impact on patient care. QT Imaging’s Breast Acoustic CT™ Scanner is an adjunctive breast imaging system that uses low-energy sound waves to create true 3D, quantitative breast images without radiation, compression, or contrast, through an operator-independent platform designed for consistent, reproducible imaging.
QT Imaging (QTI) appointed imaging industry veteran Dr. Mark L. Winkler as Chief Medical Officer as the company advances commercialization of its radiation-free breast imaging platform.
Dr. Winkler co-founded Steinberg Diagnostic Medical Imaging and led its growth to 13 outpatient imaging locations in Southern Nevada before its integration into Intermountain Health. As CMO, he will oversee medical and clinical strategy, including evidence generation, clinical studies and publications, radiologist education, and integration of QT Imaging’s Breast Acoustic CT™ and related technology into routine practice, working closely with product and commercial teams to support physician adoption.
Former CMO Dr. Elaine Iuanow will become Senior Clinical Advisor. To induce Dr. Winkler to join, QT Imaging granted an employment inducement award of RSUs covering 150,000 shares of common stock, effective September 9, 2026, with 50,000 shares vesting on November 15, 2027 and the remaining 100,000 vesting quarterly thereafter, subject to continued employment.
QT Imaging (Nasdaq: QTI) released a mid‑year 2026 CEO letter highlighting strong commercial, financial, regulatory and clinical progress for its Breast Acoustic CT platform. In the first half of 2026, the company generated $14.0 million in revenue, up 116% year over year, and shipped 28 scanners, double the prior‑year period. QT Imaging reported no revenue in 2023, followed by $4.9 million in 2024 and $18.9 million in 2025, and reiterated ~$39 million 2026 revenue guidance.
The company completed a $10 million underwritten public offering, extended its senior secured term loan maturity to March 31, 2029, and held about $14.2 million in cash and restricted cash as of August 7, 2026. QT Imaging returned to the Nasdaq Capital Market, was added to the Russell Microcap Index, and reported over 12,000 women imaged. It obtained two new FDA clearances, completed its first routine FDA inspection with zero Form 483 observations, secured regulatory authorizations in Saudi Arabia, UAE and Israel, expanded U.S. and international distribution partnerships, advanced multiple clinical studies, demonstrated <1% variability in quantitative biomarkers, and received an AMA Category III CPT code released on July 1, 2026 for 3D quantitative transmission volumetric ultrasound tomography of the breast.
QT Imaging (Nasdaq: QTI) reported strong growth for the quarter ended June 30, 2026, with second-quarter revenue of $7.4 million, up 103% from $3.7 million a year earlier, driven by shipment of 15 Breast Acoustic CT scanners. First-half 2026 revenue rose 116% to $14.0 million on 28 scanners shipped.
The company completed a $10.0 million underwritten public offering, extended its senior secured term loan maturity to March 31, 2029, and reaffirmed 2026 revenue guidance of approximately $39 million. QT Imaging reported a second-quarter gross margin of 41%, operating loss of $1.9 million, and net loss of $11.1 million (including an $8.3 million non-cash loss on debt extinguishment). Cash and restricted cash totaled $11.0 million at June 30, 2026 and $14.2 million as of August 7, 2026.
QT Imaging (Nasdaq: QTI) will report its second quarter 2026 financial results for the period ended June 30, 2026 after market close on Wednesday, August 12, 2026, and will host a conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
According to QT Imaging, participants are encouraged to pre-register online, but U.S. callers can also join by dialing 866-777-2509, and international participants can dial 412-317-5413. A live and archived webcast of the call will be accessible via a provided link and through the IR Calendar section of the QT Imaging website.
QT Imaging (Nasdaq: QTI) advanced its direct U.S. commercial strategy for the Breast Acoustic CT Scanner by appointing breast imaging industry veterans Jason Dyer as Vice President Regional Sales East and Dave Reinhart as Vice President Regional Sales West. Both joined in July 2026 and report to Chief Commercial Officer Satrajit Misra.
According to QT Imaging, these hires support a shift from a primarily distributor-led model toward an integrated direct commercial organization while maintaining its existing U.S. distribution relationship with NXC Imaging, a Canon Medical Systems USA subsidiary. The expanded commercial team will target leading medical centers and integrated delivery networks, support evidence generation, physician education, quantitative imaging biomarker development, potential therapy-monitoring applications (subject to validation and regulatory clearances), and growth of recurring software and analytics revenue, including future AI-enabled Software-as-a-Service offerings.
QT Imaging (Nasdaq: QTI) appointed Julia Albright, Ph.D., as Chief Science Officer effective July 27, 2026. She brings more than 25 years of experience across medical imaging, digital health, oncology, cloud technologies, and healthcare AI.
As CSO, Dr. Albright will lead QT Imaging’s scientific strategy, collaborating with R&D, engineering, clinical, and product teams. Her focus will include quantitative breast imaging, AI-powered image analysis, clinical evidence generation, and development of the company’s next generation, radiation-free breast imaging technologies.